Cell News and Research

RSS

ISCO fourth quarter revenue increases 110% to $1.1 million

International Stem Cell Corporation today announced year-end financial results for the year ended December 31, 2011.

21 Mar 2012

Cardium commences Generx Phase 3 registration study in myocardial ischemia

Cardium Therapeutics today announced the initiation of the ASPIRE Phase 3 registration study to evaluate the therapeutic effects of Cardium's lead product candidate, Generx (Ad5FGF-4) in patients with myocardial ischemia.

21 Mar 2012

Sharp rise recorded in cases of new strain of whooping cough: New genotype may be evading vaccine’s protective effects

Australia’s prolonged whooping cough epidemic has entered a disturbing new phase, with a study showing a new strain or genotype may be responsible for the sharp rise in the number of cases.

20 Mar 2012

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.

20 Mar 2012

n3D releases new 24-well Bio-Assembler

Only days after Rainbow BioSciences closed a deal to acquire an equity interest in Nano3D Biosciences, n3D announced the release of its groundbreaking new 24-well Bio-Assembler.

20 Mar 2012

EJSO publishes results from Cytori breast reconstruction cell therapy trial

Cytori Therapeutics announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology.

20 Mar 2012

Study determines why blood oranges develop anthocyanin pigments

The anthocyanin pigments that provide the "blood" color of blood oranges are not produced in significant amounts unless the fruit is exposed to cold conditions during its development or post-harvest. No cold exposure means poor anthocyanin production and the loss of the entire crop. This means that blood oranges can be grown in many areas of the world, but they are most likely to be exposed to the correct temperature conditions in only a few regions, including their major area of production in Sicily.

20 Mar 2012

Mayo Clinic researchers train mouse immune systems to eradicate skin cancer from within

Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors.

20 Mar 2012

New antibiotic shows promise against bovine mastitis

Food-borne diseases might soon have another warrior to contend with, thanks to a new molecule discovered by chemists at the University of Illinois. The new antibiotic, an analog of the widely used food preservative nisin, also has potential to be a boon to the dairy industry as a treatment for bovine mastitis.

20 Mar 2012

FHCRC research represents potential breakthrough in treatment of pancreas cancer

Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreas cancer.

20 Mar 2012

Hedgehog and mTOR pathway are active in esophageal cancer

Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs that attack the Hedgehog pathway.

20 Mar 2012

Circadian rhythms control production of metabolites

By analyzing the hundreds of metabolic products present in the liver, researchers with the UC Irvine Center for Epigenetics & Metabolism have discovered that circadian rhythms - our own body clock - greatly control the production of such key building blocks as amino acids, carbohydrates and lipids.

20 Mar 2012

CJC publishes updated atrial fibrillation guidelines

The Canadian Journal of Cardiology has published a focused update to the Canadian Cardiovascular Society's atrial fibrillation guidelines.

20 Mar 2012

Disruptions in immune system regulation may play a role in NEC

Despite advances in neonatal care, necrotizing enterocolitis (NEC) - the most common gastrointestinal emergency in premature infants - continues to be a deadly disease. "We haven't made a lot of progress in identifying babies early who may be at risk for NEC, preventing it or treating it," said J-rn-Hendrik Weitkamp, M.D., a neonatologist and assistant professor of Pediatrics at Monroe Carell Jr. Children's Hospital at Vanderbilt.

20 Mar 2012

Moraga announces publication of its blood-derived BLSCs patent with EPO

Moraga Biotechnology Corporation, an adult stem cell company based in Culver City, California, announces the publication of its blood-derived Blastomere-Like Stem Cells (BLSCs) patent with the European Patent Office.

20 Mar 2012

Novel technique rapidly identifies and tracks location of diseased proteins inside cells

A research team led by the University of Melbourne, Australia, has developed a novel technique that tracks diseased proteins behaving badly by forming clusters in brain diseases such as Huntington's and Alzheimer's.

19 Mar 2012

RBC Life Sciences 2011 consolidated net sales increases to $28.4 million

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $28.4 million for the year ended December 31, 2011, a 1% increase over 2010 consolidated net sales of $28.2 million.

19 Mar 2012

FDA approves key testing phase for artificial pancreas

A University of Virginia-developed artificial pancreas that could potentially automate care for millions of Type 1 diabetes patients has received U.S. Food and Drug Administration (FDA) approval for a key testing phase.

19 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

RBCC's new agreement with n3D could help develop stem-cell therapies

As global demand for innovative new stem-cell therapies grows by the day, Rainbow BioSciences' new agreement with n3D Biosciences could help to bring these therapies to market faster than ever before.

19 Mar 2012